Mantis Therapeutics objective is to employ a recently developed immunotherapy in the form of a live attenuated Salmonella enterica serovar Typhimurium vector (BaCureTM) for cancer (CRC) immunotherapy. Our BaCureTM vector, specifically targets and colonizes multiple solid tumours and we aim to offer innovative targeted immunotherapy not only against CRC and also other cancer types. BaCureTM has shown the best-in-class efficacy against CRC and other cancer types. A single dose of BaCureTM elicits 100% CRC growth inhibition and 100% renal cell carcinoma (RCC) growth inhibition in pre-clinical models proving its superior efficacy to competitive bacterial vectors and other technologies. BaCureTM therefore offers a powerful alternative to current cancer (CRC) treatment options enabling us to tap into the large market of unmet medical needs. Importantly, in the future it can serve as a valid alternative for patients that show cancer recurrence and even be recommended as first line of treatment.